

8 October 2025

Sydney, Australia

## Nyrada Board Transition and CEO Remuneration Review

**Nyrada Inc (ASX:NYR)**, a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions announces changes to its Board of Directors.

Dr Gisela Mautner has advised that she will not stand for re-election at the upcoming Annual General Meeting (AGM). She will, however, continue to serve on the Board until the conclusion of the AGM to ensure a smooth and orderly transition. Dr Mautner will also remain available to Nyrada as a consultant following the conclusion of her term as a Non-Executive Director.

Effective today, Mr James Bonnar, Chief Executive Officer of Nyrada, has been appointed to the Board as Managing Director. In accordance with Nyrada's by-laws, Mr Bonnar will also stand for election at the AGM. Due to his executive role as Chief Executive Officer, Mr Bonnar is considered non-independent.

**Nyrada Chair, John Moore, commented:** "On behalf of the Board, I would like to thank Gisela for her significant contributions during this important period of growth and transformation for Nyrada. We are pleased to welcome James to the Board and look forward to his continued leadership as the Company develops Xolatyrp™."

Furthermore, the Company's Remuneration and Nomination Committee has undertaken a review of Mr Bonnar's remuneration. Following their recommendations, the Board has today reviewed and revised Mr Bonnar's Base Remuneration, effective from 1 July 2025, to AUD\$383,574 (inclusive of superannuation).

- ENDS -



## About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both cardioprotection and neuroprotection, and has just completed a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by John Moore, Non-Executive Chair, on behalf of the Board.*

### Investor & Media Enquiries:

Dimitri Burshtein

T: 0491 789 391

E: [info@nyrada.com](mailto:info@nyrada.com)

### Company Secretary:

David Franks

T: 02 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

## Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.